# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Surface Oncology (NASDAQ:SURF) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(...
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc.
Wedbush analyst Robert Driscoll downgrades Surface Oncology (NASDAQ:SURF) from Outperform to Neutral.